Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma

por Deplanque, G, Madhusudan, S, Jones, P H, Wellmann, S, Christodoulos, K, Talbot, D C, Ganesan, T S, Blann, A, Harris, A L
Publicado 2004

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbaz...

por Propper, D J, Braybrooke, J P, Levitt, N C, O'Byrne, K, Christodoulos, K, Han, C, Talbot, D C, Ganesan, T S, Harris, A L
Publicado 2000

Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation

por Marsh, H P, Haldar, N A, Bunce, M, Marshall, S E, le Monier, K, Winsey, S L, Christodoulos, K, Cranston, D, Welsh, K I, Harris, A L
Publicado 2003

Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer

por Jones, P H, Christodoulos, K, Dobbs, N, Thavasu, P, Balkwill, F, Blann, A D, Caine, G J, Kumar, S, Kakkar, A J, Gompertz, N, Talbot, D C, Ganesan, T S, Harris, A L
Publicado 2004

Parathyroid hormone signaling in mature osteoblasts/osteocytes protects mice from age-related bone loss

por Uda, Yuhei, Saini, Vaibhav, Petty, Christopher A., Alshehri, Majed, Shi, Chao, Spatz, Jordan M., Santos, Roberto, Newell, Carly M., Huang, Tim Y., Kochen, Alejandro, Kim, Ji W., Constantinou, Christodoulos K., Saito, Hiroaki, Held, Kathryn D., Hesse, Eric, Pajevic, Paola Divieti
Publicado 2021